文献速递糖尿病

血浆富亮氨酸α-2糖蛋白1预测2型糖尿病中快速eGFR下降和白蛋白尿进展

Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本前瞻性队列研究在区域医院纳入1226例2型糖尿病患者,平均随访3.1±0.4年,发现基线血浆LRG1较高者白蛋白尿进展和CKD进展风险均较高;LRG1每增加1个标准差,白蛋白尿进展调整风险增加1.26倍,CKD进展调整风险增加1.48倍,均独立于传统危险因素。

要点

  • 基线血浆LRG1较高者发生白蛋白尿进展和CKD进展的风险均较高。
  • LRG1每增加1个标准差,白蛋白尿进展调整风险增加1.26倍(95%CI 1.04–1.53,P=0.018)。
  • LRG1每增加1个标准差,CKD进展调整风险增加1.48倍(95%CI 1.04–2.11,P=0.032)。

核心结论

  • 血浆LRG1可独立于传统危险因素预测2型糖尿病患者的白蛋白尿进展和CKD进展,可能参与导致DKD进展的病理通路。

研究设计与样本

  • 前瞻性队列研究,在区域医院纳入1226例2型糖尿病患者,平均随访3.1±0.4年。

主要发现

  • 白蛋白尿进展和CKD进展的参与者基线血浆LRG1水平均较高。
  • LRG1每增加1个标准差,白蛋白尿进展的调整风险增加1.26倍(95%CI 1.04–1.53,P=0.018)。
  • LRG1与微量白蛋白尿进展为大量白蛋白尿的关联强于正常白蛋白尿进展为微量白蛋白尿:OR 1.51(95%CI 1.04–2.18,P=0.029)vs OR 1.09(95%CI 0.86–1.37,P=0.486),均为LRG1每增加1个标准差。
  • LRG1每增加1个标准差,CKD进展的调整风险增加1.48倍(95%CI 1.04–2.11,P=0.032)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Abnormal angiogenesis plays an important role in pathogenesis of diabetic kidney disease (DKD). Leucine-rich α-2 glycoprotein 1 (LRG1) is a newly identified angiogenic factor. OBJECTIVE: To study whether plasma LRG1 may independently predict progression of DKD in individuals with type 2 diabetes mellitus (T2DM). DESIGN AND SETTING: Prospective cohort study in a regional hospital. PATIENTS: In total, 1226 T2DM participants were followed for a mean ± standard deviation (SD) of 3.1 ± 0.4 years. MAIN OUTCOMES: Albuminuria progression was defined as elevation in albuminuria level to a higher category. Chronic kidney disease (CKD) progression [rapid estimated glomerular filtration rate (eGFR) decline] was defined as a 40% or greater deterioration in eGFR in 3 years. RESULTS: Both participants with albuminuria progression and those with CKD progression had higher plasma LRG1 levels at baseline. LRG1 independently predicted albuminuria progression above traditional risk factors, including baseline eGFR and urine albumin to creatinine ratio. A 1-SD increment in LRG1 was associated with a 1.26-fold [95% confidence interval (CI), 1.04 to 1.53, P = 0.018] higher adjusted risk for albuminuria progression. The association of LRG1 with microalbuminuria to macroalbuminuria progression was stronger than its association with normoalbuminuria to microalbuminuria progression [odds ratio (OR), 1.51; 95% CI, 1.04 to 2.18, P = 0.029 vs OR, 1.09; 95% CI, 0.86 to 1.37, P = 0.486, per 1-SD LRG1 increment]. Also, LRG1 independently predicted CKD progression above traditional risk factors. A 1-SD increment in LRG1 was associated with a 1.48-fold (95% CI, 1.04 to 2.11, P = 0.032) higher adjusted risk for CKD progression. CONCLUSIONS: Plasma LRG1 predicts both albuminuria and CKD progression beyond traditional risk factors. It may play a role in the pathologic pathway leading to progression of DKD in T2DM.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu JJ, Pek SLT, Ang K, et al. Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2017. PMID: 28973352. doi:10.1210/jc.2017-00930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。